High-dose conformal radiotherapy and concomitant 5-FU, followed by gemcitabine for non-metastatic unresectable pancreatic carcinoma: A phase II prospective study.

G. van Tienhoven,W. Vervenne,V. J. Ooink,S. Phoa,M. Bruno,D. Gouma,M. Hulshof,D. Richel

DOI: https://doi.org/10.1200/jco.2004.22.14_suppl.4181

IF: 45.3

Journal of Clinical Oncology

Abstract:4181 Background: There are no standard treatment options for locally advanced pancreatic cancer (LAPC). External beam radiotherapy (RT) has frequently been used. The administered radiation doses from 45 to 65 Gy may be considered inadequate for gross tumor. Concomitant 5-FU appears to improve efficacy of RT. METHODS Treatment consisted of RT at a dose of 70 Gy, 2 Gy per fraction in 7 weeks concomitant with 5-FU, 200 mg/m2/24 h as a continuous infusion, day 1-5 every week. After chemoradiation 4 cycles of gemcitabine (Gem) 1000 mg/m2 days 1, 8 and 15/ q 4 weeks. Twenty-four patients were included. Mean age was 60 years (range: 35-74); 16 male/8 female. Local disease was confirmed by laparoscopy. RESULTS Treatment was well tolerated. Grade 3 toxicities during RT/5FU included neutropenia (1 patient), liver toxicity (1), nausea (1), vomiting (1). Seventeen out of 24 patients experienced fatigue (9 grade 1, 7 grade 2 and 1 grade 3). Grade 3 toxicities during Gem included thrombopenia (1), neutropenia (5), anaemia (1) and fatigue (3). Twenty-one completed RT/5FU; 3 (12.5%) discontinued because of disease progression. Six patients (25%) completed RT/5FU but did not start Gem because of disease progression. Fifteen patients (63%) started Gem. Nine of them did not complete 4 cycles, 6 (40%) because of disease progression during Gem, 2 because of toxicity, 1 for personal reasons. 6/24 (25%) of patients completed all planned treatment. Response rates: no radiological remissions (CR/PR) were observed. After RT/5FU 15 patients (71%) had stable disease. Median overall survival was 9 months (1-30). Median progression free survival was 4 months (1-21). CONCLUSIONS This approach is safe and tolerable. However, the lack of efficacy and the treatment duration make this approach not feasible in this patient population. Although chemoradiotherapy is considered standard treatment in many centers, our data do not support this. No significant financial relationships to disclose.